Cited by 455Diabetes Management and ResearchDiabetes Management and EducationDiabetes and associated disorders

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes

Open access

Breton, Marc D., Kanapka, Lauren G., Beck, Roy W., Ekhlaspour, Laya, Forlenza, Gregory P., Cengiz, Eda, Schoelwer, Melissa, Ruedy, Katrina J., Jost, Emily, Carria, Lori, Emory, Emma, Hsu, Liana J., Oliveri, Mary, Kollman, Craig C., Dokken, Betsy B., Weinzimer, Stuart A., DeBoer, Mark D., Buckingham, Bruce A., Cherñavvsky, Daniel, Wadwa, R. Paul·2020·New England Journal of Medicine

DOI 10.1056/nejmoa2004736PMC PMC7920146

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: A closed-loop system of insulin delivery (also called an artificial pancreas) may improve glycemic outcomes in children with type 1 diabetes. METHODS: In a 16-week, multicenter, randomized, open-label, parallel-group trial, we assigned, in a 3:1 ratio, children 6 to 13 years of age who had type 1 diabetes to receive treatment with the use of either a closed-loop system of insulin delivery (closed-loop group) or a sensor-augmented insulin pump (control group). The primary outcome was the percentage of time that the glucose level was in the target range of 70 to 180 mg per deciliter, as measured by continuous glucose monitoring. RESULTS: A total of 101 children underwent randomization (78 to the closed-loop group and 23 to the control group); the glycated hemoglobin levels at baseline ranged from 5.7 to 10.1%. The mean (±SD) percentage of time that the glucose level was in the target range of 70 to 180 mg per deciliter increased from 53±17% at baseline to 67±10% (the mean over 16 weeks of treatment) in the closed-loop group and from 51±16% to 55±13% in the control group (mean adjusted difference, 11 percentage points [equivalent to 2.6 hours per day]; 95% confidence interval, 7 to 14; P<0.001). In both groups, the median percentage of time that the glucose level was below 70 mg per deciliter was low (1.6% in the closed-loop group and 1.8% in the control group). In the closed-loop group, the median percentage of time that the system was in the closed-loop mode was 93% (interquartile range, 91 to 95). No episodes of diabetic ketoacidosis or severe hypoglycemia occurred in either group. CONCLUSIONS: In this 16-week trial involving children with type 1 diabetes, the glucose level was in the target range for a greater percentage of time with the use of a closed-loop system than with the use of a sensor-augmented insulin pump. (Funded by Tandem Diabetes Care and the National Institute of Diabetes and Digestive and Kidney Diseases; ClinicalTrials.gov number, NCT03844789.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2004736

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Self-citation
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citation
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Self-citation
Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes
Russell, S. J., El-Khatib, F. H., Sinha, M., Magyar, K. L., McKeon, K., Goergen, L. G., BALLIRO, C. A., HILLARD, M. A., Nathan, D. M., & Damiano, E. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314474 · Cited by 617
Lifetime Benefits and Costs of Intensive Therapy as Practiced in the Diabetes Control and Complications Trial
(1996) · JAMA · doi:10.1001/jama.1996.03540170053032 · Cited by 457
Home Use of an Artificial Beta Cell in Type 1 Diabetes
Thabit, H., Tauschmann, M., Allen, J. M., Leelarathna, L., Hartnell, S., Wilinska, M. E., Acerini, C. L., Dellweg, S., Benesch, C., Heinemann, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509351 · Cited by 450
Self-citation
Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial
Hovorka, R., Allen, J. M., Elleri, D., Chassin, L. J., Harris, J. R., Xing, D., Kollman, C., Hovorka, T., Larsen, A. M. F., Nodale, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61998-x · Cited by 448
Self-citation
Nocturnal Glucose Control with an Artificial Pancreas at a Diabetes Camp
Phillip, M., Battelino, T., Atlas, E., Kordonouri, O., Bratina, N., Miller, S., Biester, T., Stefanija, M. A., Muller, I., Nimri, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1206881 · Cited by 431
13. Children and Adolescents: Standards of Medical Care in Diabetes−2020
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc20-s013 · Cited by 287
Predictive low-glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: results of the PROLOG trial
Forlenza, G. P., Li, Z., Buckingham, B. A., Pinsker, J. E., Cengiz, E., Wadwa, R. P., Ekhlaspour, L., Church, M. M., Weinzimer, S. A., Jost, E., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0771 · Cited by 246
Self-citation

Show all 24 references

Sorted by citations

Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice
Phillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., Kovatchev, B. P., Messer, L. H., Parkin, C. G., Ambler-Osborn, L., et al. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac022 · Cited by 443
Self-citation
14. Children and Adolescents: Standards of Medical Care in Diabetes—2022
(2021) · Diabetes Care · doi:10.2337/dc22-s014 · Cited by 385
A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial
Bergenstal, R. M., Nimri, R., Beck, R. W., Criego, A., Laffel, L., Schatz, D., Battelino, T., Danne, T., Weinzimer, S. A., Sibayan, J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32514-9 · Cited by 344
Self-citation
American Association of Clinical Endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes
Brown, S. A., Forlenza, G. P., Bode, B. W., Pinsker, J. E., Levy, C. J., Criego, A. B., Hansen, D. W., Hirsch, I. B., Carlson, A. L., Bergenstal, R. M., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0172 · Cited by 286
Self-citation
New closed-loop insulin systems
Boughton, C. K., & Hovorka, R. (2021) · Diabetologia · doi:10.1007/s00125-021-05391-w · Cited by 290
Digital twins in medicine
Laubenbacher, R., Mehrad, B., Shmulevich, I., & Trayanova, N. A. (2024) · Nature Computational Science · doi:10.1038/s43588-024-00607-6 · Cited by 252
One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology
Breton, M. D., & Kovatchev, B. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0097 · Cited by 250
Self-citation
Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes
Ware, J., Allen, J. M., Boughton, C. K., Wilinska, M. E., Hartnell, S., Thankamony, A., de Beaufort, C. E., Schierloh, U. H. E., Fröhlich-Reiterer, E. E., Mader, J. K., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2111673 · Cited by 224
Self-citation
Multicenter, randomized trial of a bionic pancreas in type 1 diabetes
Bionic Pancreas Research Group (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2205225 · Cited by 216
Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study
Choudhary, P., Kolassa, R., Keuthage, W., Kroeger, J., Thivolet, C., Evans, M., Ré, R., de Portu, S., Vorrink, L., Shin, J., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00212-1 · Cited by 204
14. Children and Adolescents: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D. M., Johnson, E. L., et al. (2022) · Diabetes Care · doi:10.2337/dc23-s014 · Cited by 224
Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes
Wadwa, R. P., Reed, Z. W., Buckingham, B. A., DeBoer, M. D., Ekhlaspour, L., Forlenza, G. P., Schoelwer, M., Lum, J., Kollman, C., Beck, R. W., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2210834 · Cited by 191
Self-citation
Open-source automated insulin delivery in type 1 diabetes
Burnside, M. J., Lewis, D. M., Crocket, H. R., Meier, R. A., Williman, J. A., Sanders, O. J., Jefferies, C. A., Faherty, A. M., Paul, R. G., Lever, C. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203913 · Cited by 183
14. Children and Adolescents: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s014 · Cited by 173
Self-citation
Building digital twins of the human immune system: toward a roadmap
Laubenbacher, R., Niarakis, A., Helikar, T., An, G. C., Shapiro, B. E., Malik‐Sheriff, R. S., Sego, T. J., Knapp, A., Macklin, P., & Glazier, J. A. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00610-z · Cited by 169
14. Children and Adolescents: Standards of Care in Diabetes—2024
ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., et al. (2023) · Diabetes Care · doi:10.2337/dc24-s014 · Cited by 192
Self-citation
Hypoglycemia in diabetes: An update on pathophysiology, treatment, and prevention
Nakhleh, A., & Shehadeh, N. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i12.2036 · Cited by 191
Type 1 diabetes mellitus: much progress, many opportunities
Powers, A. C. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142242 · Cited by 172
ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery
Sherr, J. L., Schoelwer, M., Dos Santos, T. J., Reddy, L., Biester, T., Galderisi, A., van Dyk, J. C., Hilliard, M. E., Berget, C., & DiMeglio, L. A. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13421 · Cited by 152
Self-citation
Hybrid closed‐loop therapy: Where are we in 2021?
Leelarathna, L., Choudhary, P., Wilmot, E. G., Lumb, A. N., Street, T., Kar, P. S., & Ng, S. M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14273 · Cited by 146
Glycaemic management in diabetes: old and new approaches
Ceriello, A., Prattichizzo, F., Phillip, M., Hirsch, I. B., Mathieu, C., & Battelino, T. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00245-x · Cited by 149
Continuous glucose monitoring: The achievement of 100 years of innovation in diabetes technology
Galindo, R. J., & Aleppo, G. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108502 · Cited by 144
Disorders of ubiquitylation: unchained inflammation
Beck, D. B., Werner, A. A., Kastner, D. L., & Aksentijevich, I. A. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00778-4 · Cited by 135
Effect of a Hybrid Closed-Loop System on Glycemic and Psychosocial Outcomes in Children and Adolescents With Type 1 Diabetes
Abraham, M. B., de Bock, M. I., Smith, G. J., Dart, J., Fairchild, J. M., King, B. R., Ambler, G. R., Cameron, F. J., McAuley, S. A., KEECH, A. C., et al. (2021) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2021.3965 · Cited by 128
A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72
Beck, R. W., Kanapka, L., Breton, M. D., Brown, S. A., Wadwa, R., Buckingham, B. A., Kollman, C., & Kovatchev, B. P. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0558 · Cited by 102
Self-citation
Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes
Boughton, C. K., Allen, J. M., Ware, J., Wilinska, M. E., Hartnell, S., Thankamony, A., Randell, T. L., Ghatak, A., Besser, R. E. J., Elleri, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203496 · Cited by 113
Electrospun nanofiber-based glucose sensors for glucose detection
Du, Y., Zhang, X., Liu, P., Yu, D.-G., & Ge, R.-L. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.944428 · Cited by 87
Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial
Ware, J., Boughton, C. K., Allen, J. M., Wilinska, M. E., Tauschmann, M., Denvir, L. A., Thankamony, A., Campbell, F., Wadwa, R. P., Buckingham, B. A., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00020-6 · Cited by 102
Self-citation
International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Diabetes Technologies – Insulin Delivery
Biester, T., Berget, C., Boughton, C. K., Cudizio, L., Ekhlaspour, L., Hilliard, M. E., Reddy, L., Sap, S. N. U., Schoelwer, M. J., Sherr, J. L., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000543034 · Cited by 114
Self-citation
ISPAD Clinical Practice Consensus Guidelines 2022: Assessment and management of hypoglycemia in children and adolescents with diabetes
Abraham, M. B., Karges, B., Dovč, K., Naranjo, D. M., Arbeláez, A. M., Mbogo, J., Javelikar, G., Jones, T. W., & Mahmud, F. H. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13443 · Cited by 112
Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence
Moon, S. J., Jung, I., & Park, C. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0177 · Cited by 109
Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial
Sherr, J. L., Bode, B. W., Forlenza, G. P., Laffel, L. M., Schoelwer, M. J., Buckingham, B. A., Criego, A. B., DeSalvo, D. J., MacLeish, S. A., Hansen, D. W., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2359 · Cited by 106
Self-citation
Coordination of glucose monitoring, self-care behaviour and mental health: achieving precision monitoring in diabetes
Hermanns, N., Ehrmann, D., Shapira, A., Kulzer, B., SCHMITT, A. J., & Laffel, L. M. (2022) · Diabetologia · doi:10.1007/s00125-022-05685-7 · Cited by 97
Advances in Continuous Glucose Monitoring and Integrated Devices for Management of Diabetes with Insulin-Based Therapy: Improvement in Glycemic Control
Yoo, J. H., & Kim, J. H. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0271 · Cited by 96
A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes.
Kudva, Y. C., Raghinaru, D., Lum, J. W., Graham, T. E., Liljenquist, D., Spanakis, E. K., Pasquel, F. J., Ahmann, A., Ahn, D. T., Aleppo, G., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2415948 · Cited by 83
Self-citation
The Artificial Pancreas and Type 1 Diabetes
Nwokolo, M., & Hovorka, R. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad068 · Cited by 99
Inequity in Racial-Ethnic Representation in Randomized Controlled Trials of Diabetes Technologies in Type 1 Diabetes: Critical Need for New Standards
Aktürk, H. K., Agarwal, S., Hoffecker, L., & Shah, V. N. (2021) · Diabetes Care · doi:10.2337/dc20-3063 · Cited by 81
Twin-S: a digital twin for skull base surgery
Shu, H., Liang, R., Li, Z., Goodridge, A., Zhang, X., Ding, H., Nagururu, N. V., Sahu, M., Creighton, F. X., Taylor, R. H., et al. (2023) · International Journal of Computer Assisted Radiology and Surgery · doi:10.1007/s11548-023-02863-9 · Cited by 80
Real-World Use of a New Hybrid Closed Loop Improves Glycemic Control in Youth with Type 1 Diabetes
Messer, L. H., Berget, C., Pyle, L. L., Vigers, T., Cobry, E. C., Driscoll, K. A., & Forlenza, G. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0165 · Cited by 76
Self-citation
Better TIR, HbA1c, and less hypoglycemia in closed-loop insulin system in patients with type 1 diabetes: a meta-analysis
Jiao, X., Shen, Y., & Chen, Y. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002633 · Cited by 76
Health-Related Quality of Life and Treatment Satisfaction in Parents and Children with Type 1 Diabetes Using Closed-Loop Control
Cobry, E. C., Kanapka, L. G., Cengiz, E., CARRIA, L. R., Ekhlaspour, L., Buckingham, B. A., Hood, K. K., Hsu, L. J., Messer, L. H., Schoelwer, M. J., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0532 · Cited by 73
Self-citation
Real-world evidence supporting Tandem Control-IQ hybrid closed-loop success in the Medicare and Medicaid type 1 and type 2 diabetes populations
Forlenza, G. P., Carlson, A. L., Galindo, R. J., Kruger, D. F., Levy, C. J., McGill, J. B., Umpierrez, G., & Aleppo, G. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0206 · Cited by 70
Self-citation
Improved technology satisfaction and sleep quality with Medtronic MiniMed® Advanced Hybrid Closed-Loop delivery compared to predictive low glucose suspend in people with Type 1 Diabetes in a randomized crossover trial
Wheeler, B. J., Collyns, O. J., Meier, R. A., Betts, Z. L., Frampton, C., Frewen, C. M., Galland, B. C., Hewapathirana, N. M., Jones, S., Chan, D. S., et al. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01789-5 · Cited by 68
Current Status and Emerging Options for Automated Insulin Delivery Systems
Forlenza, G. P., & Lal, R. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0514 · Cited by 70
Self-citation
Glucose control and psychosocial outcomes with use of automated insulin delivery for 12 to 96 weeks in type 1 diabetes: a meta-analysis of randomised controlled trials
Godoi, A., Marques, I. R., Padrão, E. M. H., Mahesh, A., Hespanhol, L. C., Júnior, J. E. R. L., de Souza, I. A. F., Moreira, V. C. S., Silva, C. H., Miyawaki, I. A., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01144-4 · Cited by 79
Improvements in Parental Sleep, Fear of Hypoglycemia, and Diabetes Distress With Use of an Advanced Hybrid Closed-Loop System
Cobry, E. C., Bisio, A., Wadwa, R. P., & Breton, M. D. (2022) · Diabetes Care · doi:10.2337/dc21-1778 · Cited by 65
Self-citation
Time in range centered diabetes care
Dovč, K., & Battelino, T. (2021) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.30.1 · Cited by 66
Precision medicine in type 1 diabetes
Carr, A. L. J., Evans‐Molina, C., & Oram, R. A. (2022) · Diabetologia · doi:10.1007/s00125-022-05778-3 · Cited by 69
Predictors of Time-in-Range (70–180 mg/dL) Achieved Using a Closed-Loop Control System
Schoelwer, M. J., Kanapka, L. G., Wadwa, R. P., Breton, M. D., Ruedy, K. J., Ekhlaspour, L., Forlenza, G. P., Cobry, E. C., Messer, L. H., Cengiz, E., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0646 · Cited by 64
Self-citation
Glycemic outcomes of Advanced Hybrid Closed Loop system in children and adolescents with Type 1 Diabetes, previously treated with Multiple Daily Injections (MiniMed 780G system in T1D individuals, previously treated with MDI)
Petrovski, G., Khalaf, F. A., Campbell, J., Day, E., Almajaly, D., Hussain, K., Pasha, M., Umer, F., Hamdan, M., & Khalifa, A. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-00996-7 · Cited by 64
MiniMed 780G™ in 2- to 6-Year-Old Children: Safety and Clinical Outcomes After the First 12 Weeks
Pulkkinen, M., Varimo, T. J., Hakonen, E. T., Harsunen, M. H., Hyvönen, M. E., Janér, J., Kiiveri, S., Laakkonen, H., Laakso, S. M., Wehkalampi, K., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0313 · Cited by 60
Dual‐hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions
Infante, M., Baidal, D. A., Rickels, M. R., Fabbri, A., Skyler, J. S., Alejandro, R., & Ricordi, C. (2021) · Artificial Organs · doi:10.1111/aor.14023 · Cited by 62
Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: a randomised, controlled, cross-over, non-inferiority trial
Kariyawasam, D., Morin, C., Casteels, K., Tallec, C. L., Sfez, A., Godot, C., Huneker, E., Garrec, N., Benhamou, P., Polak, M., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00271-5 · Cited by 61
Positive impact of the bionic pancreas on diabetes control in youth 6-17 years old with type 1 diabetes: a multicenter randomized trial
Bionic Pancreas Research Group, Messer, L. H., Buckingham, B. A., Cogen, F., Daniels, M., Forlenza, G., Jafri, R. Z., Mauras, N., Muir, A., Wadwa, R. P., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0201.pub · Cited by 59
Self-citation
Real-world evidence of automated insulin delivery system use
Considine, E. G., & Sherr, J. L. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0442 · Cited by 59
Landscape of Continuous Glucose Monitoring (CGM) and Integrated CGM: Accuracy Considerations
Bailey, T. S., & Alva, S. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0236 · Cited by 60
Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes
Kanapka, L. G., Wadwa, R. P., Breton, M. D., Ruedy, K. J., Ekhlaspour, L., Forlenza, G. P., Cengiz, E., Schoelwer, M. J., Jost, E., CARRIA, L. R., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1729 · Cited by 59
Self-citation
Safety and Performance of the Tandem t:slim X2 with Control-IQ Automated Insulin Delivery System in Toddlers and Preschoolers
Ekhlaspour, L., Schoelwer, M. J., Forlenza, G. P., DeBoer, M. D., Norlander, L., Hsu, L. J., KINGMAN, R. S., Boranian, E., Berget, C., Emory, E. G., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0507 · Cited by 55
Self-citation
Safety and Efficacy of Sustained Automated Insulin Delivery Compared With Sensor and Pump Therapy in Adults With Type 1 Diabetes at High Risk for Hypoglycemia: A Randomized Controlled Trial
Renard, É., Joubert, M., Villard, O., Dreves, B., Reznik, Y., Farret, A., Place, J., Breton, M. D., & Kovatchev, B. P. (2023) · Diabetes Care · doi:10.2337/dc23-0685 · Cited by 56
Self-citation
Benefits and Challenges of Current Closed-Loop Technologies in Children and Young People With Type 1 Diabetes
Fuchs, J., & Hovorka, R. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.679484 · Cited by 51
Advanced Closed-Loop Control System Improves Postprandial Glycemic Control Compared With a Hybrid Closed-Loop System Following Unannounced Meal
Garcia-Tirado, J., Diaz, J. L., Esquivel-Zuniga, R., Koravi, C. L. K., Corbett, J. P., Dawson, M., Wakeman, C., Barnett, C. L., Oliveri, M. C., Myers, H., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0932 · Cited by 52
Self-citation
Barriers to Uptake of Insulin Technologies and Novel Solutions
PAULEY, M. E., Berget, C., Messer, L. H., & Forlenza, G. P. (2021) · Medical Devices Evidence and Research · doi:10.2147/mder.s312858 · Cited by 51
Self-citation
Real-World Use of Control-IQ Technology Is Associated with a Lower Rate of Severe Hypoglycemia and Diabetic Ketoacidosis Than Historical Data: Results of the Control-IQ Observational (CLIO) Prospective Study
Graham, R., Müeller, L., Manning, M., HABIF, S., Messer, L. H., Pinsker, J. E., & Aronoff-Spencer, E. S. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0341 · Cited by 49
Biobehavioral Changes Following Transition to Automated Insulin Delivery: A Large Real-life Database Analysis
Kovatchev, B. P., Singh, H., Mueller, L., & Gonder-Frederick, L. A. (2022) · Diabetes Care · doi:10.2337/dc22-1217 · Cited by 49
The History, Evolution and Future of Continuous Glucose Monitoring (CGM)
Bender, C., Vestergaard, P., & Cichosz, S. L. (2025) · Diabetology · doi:10.3390/diabetology6030017 · Cited by 43
CGM accuracy: Contrasting CE marking with the governmental controls of the USA ( FDA ) and Australia ( TGA ): A narrative review
Pemberton, J. S., Wilmot, E. G., Barnard‐Kelly, K., Leelarathna, L., Oliver, N., Randell, T., Taplin, C. E., Choudhary, P., & Adolfsson, P. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14962 · Cited by 44
Advanced hybrid artificial pancreas system improves on unannounced meal response - In silico comparison to currently available system
Garcia‐Tirado, J., Lv, D., Corbett, J. P., Colmegna, P. H., & Breton, M. D. (2021) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2021.106401 · Cited by 46
Self-citation
Assessment of Meal Anticipation for Improving Fully Automated Insulin Delivery in Adults With Type 1 Diabetes
Garcia‐Tirado, J., Colmegna, P. H., Villard, O., Diaz, J. L., Esquivel-Zuniga, R., Koravi, C. L. K., Barnett, C. L., Oliveri, M. C., Fuller, M. R., Brown, S. A., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0119 · Cited by 45
Self-citation
Bihormonal fully closed-loop system for the treatment of type 1 diabetes: a real-world multicentre, prospective, single-arm trial in the Netherlands
van Bon, A. C., Blauw, H., Jansen, T. J. P., Laverman, G. D., Urgert, T., Geessink-Mennink, J., Mulder, A. H. L., Out, M., Veldman, R. G., Onvlee, A. J., et al. (2024) · The Lancet Digital Health · doi:10.1016/s2589-7500(24)00002-5 · Cited by 45
Human-machine co-adaptation to automated insulin delivery: a randomised clinical trial using digital twin technology
Kovatchev, B. P., Colmegna, P. H., Pavan, J., C., J. L. D., Villa-Tamayo, M. F., Koravi, C. L. K., Santini, G., Alix, C., Stumpf, M. M., & Brown, S. A. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01679-y · Cited by 50
Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility
Cobelli, C., & Kovatchev, B. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231195081 · Cited by 46
Automated insulin delivery systems: from early research to routine care of type 1 diabetes
Renard, É. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01929-5 · Cited by 50
Pre‐school and school‐aged children benefit from the switch from a sensor‐augmented pump to an AndroidAPS hybrid closed loop: A retrospective analysis
Petruželková, L., Jiranova, P., Šoupal, J., Kozak, M., Plachý, L., Neuman, V., Průhová, Š., Obermannová, B., Koloušková, S., & Šumnı́k, Z. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13190 · Cited by 43
Review of automated insulin delivery systems for individuals with type 1 diabetes: tailored solutions for subpopulations
Aiello, E. M., Deshpande, S., Özaslan, B., Wolkowicz, K. L., Dassau, E., Pinsker, J. E., & Doyle, F. J. (2021) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2021.100312 · Cited by 44
Closed-loop insulin delivery: update on the state of the field and emerging technologies
Ware, J., & Hovorka, R. (2022) · Expert Review of Medical Devices · doi:10.1080/17434440.2022.2142556 · Cited by 47
Practical Aspects and Exercise Safety Benefits of Automated Insulin Delivery Systems in Type 1 Diabetes
Zaharieva, D. P., Morrison, D., Paldus, B., Lal, R., Buckingham, B. A., & O'Neal, D. N. (2023) · Diabetes Spectrum · doi:10.2337/dsi22-0018 · Cited by 43
Self-citation
Efficacy and Safety of Tandem Control IQ Without User-Initiated Boluses in Adults with Uncontrolled Type 1 Diabetes
Aktürk, H. K., Snell‐Bergeon, J. K., & Shah, V. N. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0162 · Cited by 42
The efficacy of automated insulin delivery systems in children and adolescents with type 1 diabetes Mellitus: A systematic review and meta-analysis of randomized controlled trials
Michou, P., Gkiourtzis, Ν., Christoforidis, A., Kotanidou, E. P., & Galli-Tsinopoulou, A. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110678 · Cited by 46
Insulin Pump Utilization in 2017–2021 for More Than 22,000 Children and Adults With Type 1 Diabetes: A Multicenter Observational Study
Gandhi, K. K., Ebekozien, O. A., Noor, N., McDonough, R., Hsieh, S., Miyazaki, B., Dei-Tutu, S. A., Golden, L., Desimone, M. E., Hardison, H., et al. (2023) · Clinical Diabetes · doi:10.2337/cd23-0055 · Cited by 42
Essential Continuous Glucose Monitoring Metrics: The Principal Dimensions of Glycemic Control in Diabetes
Montaser, E., Fabris, C., & Kovatchev, B. P. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0104 · Cited by 44
In‐home use of a hybrid closed loop achieves time‐in‐range targets in preschoolers and school children: Results from a randomized, controlled, crossover trial
Berge, T. V. D., Remus, K., Biester, S., Reschke, F., Klusmeier, B., Adolph, K., Holtdirk, A., Thomas, A., Kordonouri, O., Danne, T., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14706 · Cited by 42
A multicenter randomized trial evaluating fast-acting insulin aspart in the bionic pancreas in adults with type 1 diabetes
Bionic Pancreas Research Group, Beck, R. W., Russell, S. J., Damiano, E. R., El-Khatib, F. H., Ruedy, K. J., Balliro, C., Li, Z., & Calhoun, P. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0167 · Cited by 40
Self-citation
Efficacy and safety of closed-loop insulin delivery versus sensor-augmented pump in the treatment of adults with type 1 diabetes: A systematic review and meta-analysis of randomized-controlled trials
Fang, Z., Liu, M., Tao, J., Li, C., Zou, F., & Zhang, W. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01674-6 · Cited by 38
Clinical Implementation of the Omnipod 5 Automated Insulin Delivery System: Key Considerations for Training and Onboarding People With Diabetes
Berget, C., Sherr, J. L., DeSalvo, D. J., KINGMAN, R. S., Stone, S. L., Brown, S. A., Nguyen, A., Barrett, L., Ly, T. T., & Forlenza, G. P. (2021) · Clinical Diabetes · doi:10.2337/cd21-0083 · Cited by 39
Self-citation
Novel Detection and Progression Markers for Diabetes Based on Continuous Glucose Monitoring Data Dynamics
Montaser, E., Farhy, L. S., & Kovatchev, B. P. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae379 · Cited by 45
Practical implementation of automated closed-loop insulin delivery: A French position statement
Tubiana‐Rufi, N., Schaepelynck, P., Franc, S., Chaillous, L., Joubert, M., Renard, É., Reznik, Y., Abettan, C., Bismuth, É., Beltrand, J., et al. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.10.004 · Cited by 42
Real-World Glycemic Outcomes with Early Omnipod 5 Use in Youth with Type 1 Diabetes
Marks, B. E., Meighan, S. S., Zehra, A., Douvas, J. L., Rearson, A., Suresh, R., Brown, E. A., & Wolf, R. M. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0337 · Cited by 39
Beneficial effects of Control-IQ automated insulin delivery in basal-bolus and basal-only insulin users with type 2 diabetes
Levy, C. J., Raghinaru, D., Kudva, Y. C., Pandit, K., Blevins, T., Casaubon, L., Desjardins, D., Levister, C. M., O’Malley, G., Reid, C., et al. (2024) · Clinical Diabetes · doi:10.2337/cd23-0025 · Cited by 37
Self-citation
First use of open-source automated insulin delivery AndroidAPS in full closed-loop scenario: Pancreas4ALL randomized pilot study
Petruzelkova, L., Neuman, V., Plachy, L., Kozak, M., Obermannova, B., Kolouskova, S., Pruhova, S., & Sumnik, Z. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0562 · Cited by 40
The Effect of Control IQ Hybrid Closed Loop Technology on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes
Scully, K. J., Palani, G., Zheng, H., Moheet, A. A., & Putman, M. S. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0354 · Cited by 38
A Randomized Trial of Closed-Loop Insulin Delivery Postpartum in Type 1 Diabetes
Donovan, L., Feig, D. S., Lemieux, P., Murphy, H. R., Bell, R. C., Sigal, R. J., Ho, J., Virtanen, H., Crawford, S. G., & Yamamoto, J. M. (2023) · Diabetes Care · doi:10.2337/dc23-0882 · Cited by 37
Neural-Net Artificial Pancreas: A Randomized Crossover Trial of a First-in-Class Automated Insulin Delivery Algorithm
Kovatchev, B. P., Castillo, A., Pryor, E. C., Kollar, L. L., Barnett, C. L., DeBoer, M. D., Brown, S. A., & for the NAP Study Team (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0469 · Cited by 43
Self-citation
Current Management of Glycemia in Children with Type 1 Diabetes Mellitus
Sperling, M. A., & Laffel, L. M. (2022) · New England Journal of Medicine · doi:10.1056/nejmcp2112175 · Cited by 37
Automated Insulin Delivery with SGLT2i Combination Therapy in Type 1 Diabetes
Garcia‐Tirado, J., Farhy, L. S., Nass, R. M., Kollar, L. L., Oliveri, M. C., Basu, R., Kovatchev, B. P., & Basu, A. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0542 · Cited by 37
Self-citation
Sick day management in children and adolescents with diabetes
Phelan, H., Hanås, R., Hofer, S. E., James, S., Landry, A., Lee, W., Wood, J., & Ethel Codner, D. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13415 · Cited by 41
Therapy Settings Associated with Optimal Outcomes for t:slim X2 with Control-IQ Technology in Real-World Clinical Care
Messer, L. H., & Breton, M. D. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0308 · Cited by 36
Self-citation
Automated Insulin Delivery Systems and Glucose Management in Children and Adolescents With Type 1 Diabetes
Visser, H. S. D., Waraich, S., Chhabra, M., Yamamoto, J. M., Zenlea, I. S., Askin, N., Rabbani, R., McGavock, J., TEAM Trial Patient Coresearchers, Greenberg, D. T., et al. (2025) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2025.2740 · Cited by 39
A Comparison of Two Hybrid Closed-Loop Systems in Italian Children and Adults With Type 1 Diabetes
Bassi, M., Teliti, M., Lezzi, M., Iosca, A., Strati, M. F., Carmisciano, L., d’Annunzio, G., Minuto, N., & Maggi, D. C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.802419 · Cited by 35
Continuous Glucose Monitor, Insulin Pump, and Automated Insulin Delivery Therapies for Type 1 Diabetes: An Update on Potential for Cardiovascular Benefits
PAULEY, M. E., Tommerdahl, K. L., Snell‐Bergeon, J. K., & Forlenza, G. P. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01799-x · Cited by 39
Self-citation

Authors: Breton, M. D., Kanapka, L. G., Beck, R. W., Ekhlaspour, L., Forlenza, G. P., Cengiz, E., Schoelwer, M., Ruedy, K. J., Jost, E., Carria, L., Emory, E., Hsu, L. J., Oliveri, M., Kollman, C. C., Dokken, B. B., Weinzimer, S. A., DeBoer, M. D., Buckingham, B. A., Cherñavvsky, D., & Wadwa, R. P.
Affiliations: Stanford Medicine (US)
Yale University (US)
ORCID: Breton, Marc D.
Kanapka, Lauren G.
Beck, Roy W.
Ekhlaspour, Laya
Forlenza, Gregory P.
Cengiz, Eda
Schoelwer, Melissa
Jost, Emily
Oliveri, Mary
Kollman, Craig C.
Weinzimer, Stuart A.
DeBoer, Mark D.
Buckingham, Bruce A.
Cherñavvsky, Daniel
Wadwa, R. Paul
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2020-08-27
Volume: 383
Issue: 9
Pages: 836-845
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2004736
PMC: PMC7920146
OpenAlex: W3080244655
Semantic Scholar: b2dc01402e937edd688a968cc993faf797fe24ad
Cited by: 455
References: 24
Citations by year: 2026: 54 · 2025: 68 · 2024: 65 · 2023: 84 · 2022: 88 · 2021: 78 · 2020: 15
FWCI: 49.97
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
HAL (submittedVersion)
Funders: Tandem Diabetes
National Institute of Diabetes and Digestive and Kidney Diseases
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords: type 1 diabetes, children, artificial pancreas, sensor-augmented pump, glycemic control, continuous glucose monitoring, hypoglycemia, HbA1c, diabetes technology, diabetic ketoacidosis, glycemic variability
MeSH terms: Adolescent, Blood Glucose, Child, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Insulin Infusion Systems, Male, Infusion Pumps, Implantable, Diabetic Ketoacidosis, Pancreas, Artificial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks